It’s an indubitable fact that the US sits at the top of the Biopharma industry. For the US, there is no limit to the innovation, discovery, or outsourcing of manufacturing and research facilities with their next-generation flexible manufacturing offered by numerous CDMOs and CROs. In 2023, the US government allocated 16.5 % of its GDP…
